Edesa Biotech Revenue vs. Total Debt
| EDSA Stock | USD 1.94 0.14 7.78% |
Total Revenue | First Reported 2010-03-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 536.1 K |
For Edesa Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Edesa Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Edesa Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Edesa Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Edesa Biotech over time as well as its relative position and ranking within its peers.
Edesa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Edesa Biotech Total Debt vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth. Edesa Biotech is rated # 4 in revenue category among its peers. It is rated below average in total debt category among its peers making up about 39.73 of Total Debt per Revenue. At present, Edesa Biotech's Total Revenue is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.Edesa Revenue vs. Competition
Edesa Biotech is rated # 4 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 296.83 Million. Edesa Biotech adds roughly 500 in revenue claiming only tiny portion of equities under Health Care industry.
Edesa Total Debt vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Edesa Biotech |
| = | 500 |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Edesa Biotech |
| = | 19.87 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Edesa Total Debt vs Competition
Edesa Biotech is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 279.89 Million. Edesa Biotech adds roughly 19,867 in total debt claiming only tiny portion of equities under Health Care industry.
Edesa Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Edesa Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Edesa Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Edesa Biotech's change in net profit over the period of time. It can combine multiple indicators of Edesa Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -242.6 K | -230.5 K | |
| Operating Income | -7 M | -7.4 M | |
| Income Before Tax | -6.2 M | -6.5 M | |
| Total Other Income Expense Net | 845.5 K | 887.8 K | |
| Net Loss | -6.2 M | -6.5 M | |
| Income Tax Expense | 720.00 | 1,354 | |
| Interest Income | 260.9 K | 273.9 K | |
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -7.5 M | -7.9 M | |
| Net Interest Income | 333.3 K | 350 K | |
| Change To Netincome | 2.6 M | 2.7 M | |
| Net Loss | (1.93) | (46.75) | |
| Income Quality | 0.79 | 0.51 | |
| Net Income Per E B T | 1.00 | 1.00 |
Edesa Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Edesa Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Edesa Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Edesa Biotech's important profitability drivers and their relationship over time.
Use Edesa Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.Edesa Biotech Pair Trading
Edesa Biotech Pair Trading Analysis
The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Edesa Biotech position
In addition to having Edesa Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recycling Thematic Idea Now
Recycling
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
To fully project Edesa Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Edesa Biotech's income statement, its balance sheet, and the statement of cash flows.